Syndax Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SYNDAX
SYNDAX has one approved drug.
There are three US patents protecting SYNDAX drugs.
Summary for Syndax
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Syndax
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Syndax | REVUFORJ | revumenib citrate | TABLET;ORAL | 218944-001 | Nov 15, 2024 | RX | Yes | No | 11,479,557 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Syndax | REVUFORJ | revumenib citrate | TABLET;ORAL | 218944-003 | Nov 15, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Syndax | REVUFORJ | revumenib citrate | TABLET;ORAL | 218944-003 | Nov 15, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Syndax Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2021258089 | ⤷ Start Trial |
| New Zealand | 748203 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2021207335 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
